Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.65 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | ALPG | P10696 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1557262 | 0.94 | PTGS2 (0.62) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL12557393 | 0.94 | PTGS2 (0.58) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL1557261 | 0.94 | PTGS2 (0.62) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL2608346 | 0.94 | PTGS2 (0.62) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL16229610 | 0.93 | PTGS2 (0.57) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL16229624 | 0.93 | PTGS2 (0.57) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL12590030 | 0.91 | GAA (0.56) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL12590243 | 0.91 | PTGS2 (0.56) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL12590050 | 0.90 | PTGS2 (0.55) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL12590026 | 0.90 | PTGS2 (0.55) | PTGS2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305638-B1 | ASYMMETRIC AZINE COMPOUND AND METHOD FOR PRODUCING THE SAME | ZEON CORP (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-8871977-B2 | Asymmetric azine compound and method for producing the same | ZEON CORPORATION (JP) | 2014-10-28 | — | — | US | disclosed |
| US-8158021-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, liquid crystalline polymer, and optical anisotropic article | ZEON CORPORATION (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20110144379-A1 | ASYMMETRIC AZINE COMPOUND AND METHOD FOR PRODUCING THE SAME | ZEON CORPORATION (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20100258764-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE | ZEON CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100258764-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE | LEO1, ZYX, CCNT1 | PTGS2 2370/4885CA12 66/4885CA1 75/4885 |
| US-20110144379-A1 | ASYMMETRIC AZINE COMPOUND AND METHOD FOR PRODUCING THE SAME | ADH5, ADH1C, ADH1A | PTGS2 3569/4885CA12 635/4885CA1 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.